Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EDITORIAL: What's in store at MHRA under NICE man Rawlins?

This article was originally published in Scrip

Executive Summary

The appointment of Professor Sir Michael Rawlins as chair of the UK Medicines and Healthcare Products Regulatory Agency will capture the attention of anyone with even a passing interest in the future of drug and medical device regulation.

You may also be interested in...



Preparing To Lead EMA, Cooke Routes Road Ahead For Pharma Regulation At Agency Conference

Change in leadership at the European Medicines Agency comes at a critical time.

Emer Cooke Prepares To Take Over As Head Of EMA

The change in leadership at the European Medicines Agency comes at a critical time.

EU Accelerated Assessment Tracker

Another three marketing authorization applications will be fast-tracked through the centralized review process at the European Medicines Agency. The Pink Sheet tracker logs these and other developments relating to the agency's accelerated assessment mechanism.

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel